On May 7th, recently, Jianshi Bio, a domestic minimally invasive interventional treatment company for heart valves, completed tens of millions of RMB A round of financing, led by Chen De Capital.
Jianshi Bio focuses on the innovation of minimally invasive interventional therapy for heart valves. At present, it has established an international vision management team led by Dr. Haigui. The core R&D personnel have served in many well-known cardiovascular companies at home and abroad. R&D experience in the fields of bioprosthetic technology, stent design, etc.
Jianshi Biological's internationally leading and domestically-made transcatheter tricuspid valve replacement system (Lux-Valveò) fills the gap in domestic tricuspid valve replacement products. At the TCT2017, the most influential transcatheter technology conference held in Denver, USA in 2017, the appearance of Lux-Valveò attracted great attention from the participating experts. The product is expected to enter the clinical trial phase in 2019.
In addition, the company successfully developed the leading transcatheter aortic valve replacement system (Ken-Valveò), its unique design ensures that the valve can be used not only for the treatment of aortic valve stenosis, but also for aortic regurgitation (insufficiency) . In China, patients with reflux caused by aortic valve insufficiency are no less than patients with aortic stenosis. Therefore, the valve is an independent research and development achievement that fully conforms to China's national conditions.
In 2013, Jianshi Bio was approved as the Zhixing Entrepreneurship Project of Ningbo Science and Technology Bureau of Zhejiang Province. In 2014, it was awarded the title of Technology Innovation Team of Hangzhou Bay New District of Ningbo City and the project fund. The company's participation in the "Animal Source Tissue or Organ Immunogenicity Elimination and Anti-calcification Technology" project was supported by the 2016 National Key Research and Development Program of the Ministry of Science and Technology. In the same year, the “Minimally Invasive Interventional Aortic Stent Valve System†project was successfully funded by the Ningbo Industrial Major Project-Life Health Project.
At present, the company has established long-term cooperative relations with many well-known top three hospitals in China. In 2017, the National Innovation and Entrepreneurship Competition won the title of Outstanding Enterprise in the National Finals.
Dr. Cao Peng, General Manager of Jianshi Biotechnology, said: "Transcatheter interventional technique is an important direction for the future development of heart valve disease treatment. At present, aortic valve intervention in developed countries is relatively mature, and China is in a period of rapid development. The more hospitals that carry out such operations, the more patients who have no previous treatments have benefited. With the support of the independent innovation policy advocated by the state, the interventional valves independently developed by the Chinese have gradually entered the international arena, and many aspects have achieved the bend. Road overtaking."
Wu Jiayu, a partner of Chende Capital, said: "In the past ten years, the development of cardiovascular minimally invasive interventions has been bumpy, and the two high-end devices, RDN and absorbable stents, have experienced twists and turns. The cardiac interventional valve has become the only basic medicine. Chende Capital has a number of layouts in the field of cardiovascular intervention. While optimistic about this direction, it also knows that the technical barriers need long-term accumulation to break through."
Dental Suction Unit,Dental Suction Machine,Mobile Dental Suction Unit,Portable Dental Suction Unit
ZHEJIANG FOMOS MEDICAL TECHNOLOGY CO.,LTD. , https://www.ifomos.com